Filtreler
Oxidative parameters, oxidative DNA damage, and urotensin-II in schizoaffective disorder patients

Kilic, Osman Hasan Tahsin | Aksoy, Ihsan | Elboga, Gulcin Cinpolat | Bulbul, Feridun

Article | 2019 | PSYCHIATRY AND CLINICAL PSYCHOPHARMACOLOGY29 ( 2 ) , pp.151 - 157

OBJECTIVE: Complexity of schizoaffective disorder makes the identification of its pathophysiology a great challenge and there are very limited published data about the role of oxidative stress. Oxidative DNA damage has not been investigated in schizoaffective disorder. Therefore, we aimed to evaluate oxidative DNA damage together with oxidative stress and urotensin-II in patients with schizoaffective disorder. METHODS: Fifty-four patients who were diagnosed as schizoaffective disorder bipolar type (27 of them were in symptomatic remission and 27 of them were not) and 27 healthy volunteers were included in the study. Total antioxidan . . .t status (TAS), total oxidant status (TOS), oxidative stress index (OSI), serum 8-hydroxy-2'-deoxyguanosine (8-OHdG), and urotensin-II (U-II) levels were calculated and evaluated. RESULTS: TAS and U-II levels were found to be lower in the patient group with and without remission when compared with the control group separately. There were no significant difference in terms of TOS, OSI, and 8-OHdG. Similar results were obtained when those in symptomatic remission and non-remission patient groups were combined and compared with the control group. CONCLUSION: TAS levels in schizoaffective disorder patients were lower than controls, which may mean a vulnerability to the oxidative stress but there were no differences in terms of oxidative DNA damage. U-II levels in schizoaffective disorder patients were significantly lower than controls in contrast with our previous study Daha fazlası Daha az

N-acetylcysteine may reduce repetitive behaviors in children with autism: a case series

Celebi, Fahri | Koyuncu, Ahmet | Coskun, Murat

Article | 2017 | PSYCHIATRY AND CLINICAL PSYCHOPHARMACOLOGY27 ( 2 ) , pp.190 - 193

Objective: Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by impairment in social communication and interaction, and restricted, stereotypic, repetitive behaviors. Behavioral problems are common in children with ASD. Herein, we report the effect of N-acetylcysteine (NAC) treatment on repetitive behaviors in 10 children with ASD. Methods: Ten children with ASD were assessed using the Childhood Autism Rating Scale and Aberrant Behavior Checklist (ABC). The clinical follow-up was performed with ABC and Clinical Global Impressions-Improvement (CGI-I). A total of 10 patients were initiated on NAC therapy in . . . addition to their treatment with a stable dose of risperidone to avoid the potential adverse effects of higher doses of risperidone. Two patients discontinued NAC treatment before the third week. Eight patients were treated with an NAC dosage of 1200-2700 mg/day for 6-10 weeks. Results: The mean age of the patients was 8.6 years. Patients received NAC treatment for a mean duration of 8.25 weeks and a mean dosage of 2100 mg/day. Improvement in stereotypic behaviors was statistically significant in addition to the improvement in mean CGI-I score (p =.025 and .006, respectively). Conclusion: NAC adjunction to risperidone treatment may be helpful to reduce repetitive behaviors in children with ASD with limited adverse effects and good tolerability Daha fazlası Daha az

Electroconvulsive therapy combined with antipsychotic therapy in the treatment of acute schizophrenia inpatients: symptom profile of the clinical response

Ipekcioglu, Derya | Yazar, Menekse Sila | Canbek, Ozge | Yuksel, Ozge | Meterelliyoz, Kumru Senyasar | Ilnem, Mehmet Cem

Article | 2018 | PSYCHIATRY AND CLINICAL PSYCHOPHARMACOLOGY28 ( 4 ) , pp.363 - 370

OBJECTIVE: The aim of the study was to examine the efficacy of electroconvulsive therapy (ECT) combined with antipsychotic (AP) medication on symptom profile in patients with a diagnosis of schizophrenia who had received acute psychiatric inpatient treatment. METHODS: In this prospective study, patients were evaluated for inclusion in the study who were diagnosed with schizophrenia according to DSM-IV diagnostic criteria and were to receive ECT. The patients were evaluated using the Brief Psychiatric Rating Scale (BPRS), Scale for the Assessment of Positive Symptoms (SAPS), Scale for the Assessment of Negative Symptoms (SANS), and C . . .linical Global Impression - Improvement (CGI-I) sub-scale before the first session ECT, once following every two subsequent sessions and after the final session. RESULTS: The patients showed significant improvements in BPRS scores at each evaluation compared with their scores at baseline, and a significant clinical improvement was found on the CGI-I sub-scale at the end of treatment. Across all SAPS sub-scores, significant decreases were found, and the symptoms related to hallucinations and positive formal thought disorder showed the most rapid response to treatment. Across all SANS sub-scores, significant decreases were found, and affective flattening or blunting symptoms responded most rapidly to treatment. CONCLUSION: One of the most important findings in the present study of hospitalized patients with acute schizophrenia was the good response to treatment, which provided significant improvements in both positive and negative symptoms. The most rapid response to treatment was found for hallucinations, positive formal thought disorder, and affective flattening or blunting symptoms. The most important limitation of our study may be the small number of cases. In future, well-standardized studies using a double-blinded, comparative, prospective design and including a sufficient number of patients are needed Daha fazlası Daha az

6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms